JP2021521281A - 創傷および皮膚障害を治療するためのタラ肝油で構成される局所用組成物 - Google Patents
創傷および皮膚障害を治療するためのタラ肝油で構成される局所用組成物 Download PDFInfo
- Publication number
- JP2021521281A JP2021521281A JP2021505627A JP2021505627A JP2021521281A JP 2021521281 A JP2021521281 A JP 2021521281A JP 2021505627 A JP2021505627 A JP 2021505627A JP 2021505627 A JP2021505627 A JP 2021505627A JP 2021521281 A JP2021521281 A JP 2021521281A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- oil
- range
- composition
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003026 cod liver oil Substances 0.000 title claims abstract description 137
- 235000012716 cod liver oil Nutrition 0.000 title claims abstract description 136
- 239000000203 mixture Substances 0.000 title claims description 605
- 238000011282 treatment Methods 0.000 title abstract description 39
- 230000000699 topical effect Effects 0.000 title abstract description 28
- 208000017520 skin disease Diseases 0.000 title abstract description 15
- 208000027418 Wounds and injury Diseases 0.000 title description 190
- 206010052428 Wound Diseases 0.000 title description 182
- 102000008186 Collagen Human genes 0.000 claims abstract description 333
- 108010035532 Collagen Proteins 0.000 claims abstract description 333
- 229920001436 collagen Polymers 0.000 claims abstract description 333
- 241000251468 Actinopterygii Species 0.000 claims abstract description 180
- -1 cetyl ester Chemical class 0.000 claims abstract description 136
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims abstract description 115
- 239000010460 hemp oil Substances 0.000 claims abstract description 114
- 239000003240 coconut oil Substances 0.000 claims abstract description 102
- 235000019864 coconut oil Nutrition 0.000 claims abstract description 102
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 100
- 235000019482 Palm oil Nutrition 0.000 claims abstract description 93
- 239000002540 palm oil Substances 0.000 claims abstract description 93
- 241001677259 Acanthophoenix rubra Species 0.000 claims abstract description 89
- 235000021588 free fatty acids Nutrition 0.000 claims abstract description 77
- 239000012141 concentrate Substances 0.000 claims abstract description 70
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 69
- 239000011780 sodium chloride Substances 0.000 claims abstract description 67
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 67
- 239000008158 vegetable oil Substances 0.000 claims abstract description 65
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims abstract description 43
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims abstract description 43
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims abstract description 42
- 235000013871 bee wax Nutrition 0.000 claims abstract description 18
- 239000012166 beeswax Substances 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 229940057917 medium chain triglycerides Drugs 0.000 claims abstract description 5
- 239000003921 oil Substances 0.000 claims description 175
- 235000019198 oils Nutrition 0.000 claims description 175
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 70
- 229930195729 fatty acid Natural products 0.000 claims description 70
- 239000000194 fatty acid Substances 0.000 claims description 70
- 239000000084 colloidal system Substances 0.000 claims description 62
- 150000004665 fatty acids Chemical class 0.000 claims description 57
- 150000003626 triacylglycerols Chemical class 0.000 claims description 57
- 230000000202 analgesic effect Effects 0.000 claims description 37
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 33
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 33
- 239000003009 skin protective agent Substances 0.000 claims description 31
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims description 24
- 229940033080 omega-6 fatty acid Drugs 0.000 claims description 24
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 22
- 239000006014 omega-3 oil Substances 0.000 claims description 21
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 20
- 235000021323 fish oil Nutrition 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 11
- 208000002193 Pain Diseases 0.000 claims description 11
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 10
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 10
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 10
- 210000004185 liver Anatomy 0.000 claims description 10
- 230000002209 hydrophobic effect Effects 0.000 claims description 9
- 239000013078 crystal Substances 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 235000008504 concentrate Nutrition 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 2
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims 3
- ZBCATMYQYDCTIZ-UHFFFAOYSA-N 4-methylcatechol Chemical compound CC1=CC=C(O)C(O)=C1 ZBCATMYQYDCTIZ-UHFFFAOYSA-N 0.000 claims 1
- DCAYPVUWAIABOU-UHFFFAOYSA-N alpha-n-hexadecene Natural products CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 claims 1
- 239000010696 ester oil Substances 0.000 claims 1
- 239000003223 protective agent Substances 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 abstract description 19
- 206010072170 Skin wound Diseases 0.000 abstract description 7
- 210000003491 skin Anatomy 0.000 description 250
- 235000019688 fish Nutrition 0.000 description 175
- 230000008018 melting Effects 0.000 description 59
- 238000002844 melting Methods 0.000 description 59
- 206010000496 acne Diseases 0.000 description 55
- 239000011148 porous material Substances 0.000 description 54
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 50
- 238000009472 formulation Methods 0.000 description 50
- 208000002874 Acne Vulgaris Diseases 0.000 description 49
- 239000003963 antioxidant agent Substances 0.000 description 48
- 235000006708 antioxidants Nutrition 0.000 description 48
- 235000019645 odor Nutrition 0.000 description 45
- 239000000047 product Substances 0.000 description 45
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 44
- 239000001993 wax Substances 0.000 description 44
- 235000021466 carotenoid Nutrition 0.000 description 42
- 150000001747 carotenoids Chemical class 0.000 description 42
- 239000000758 substrate Substances 0.000 description 42
- 150000003839 salts Chemical class 0.000 description 39
- 230000005496 eutectics Effects 0.000 description 36
- 210000001519 tissue Anatomy 0.000 description 34
- 239000003642 reactive oxygen metabolite Substances 0.000 description 31
- 150000001875 compounds Chemical class 0.000 description 28
- 238000000034 method Methods 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 229930003427 Vitamin E Natural products 0.000 description 24
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 24
- 235000019165 vitamin E Nutrition 0.000 description 24
- 239000011709 vitamin E Substances 0.000 description 24
- 229940046009 vitamin E Drugs 0.000 description 24
- 230000003078 antioxidant effect Effects 0.000 description 23
- 239000004615 ingredient Substances 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 22
- 230000001580 bacterial effect Effects 0.000 description 21
- 239000003814 drug Substances 0.000 description 19
- 230000008595 infiltration Effects 0.000 description 19
- 238000001764 infiltration Methods 0.000 description 19
- 230000006378 damage Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 230000035876 healing Effects 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 201000004700 rosacea Diseases 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 239000003925 fat Substances 0.000 description 16
- 235000019197 fats Nutrition 0.000 description 16
- 239000000499 gel Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 14
- 101710137760 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 14
- 241001303601 Rosacea Species 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- 229960004194 lidocaine Drugs 0.000 description 14
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 14
- 201000004624 Dermatitis Diseases 0.000 description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 13
- 239000003205 fragrance Substances 0.000 description 13
- 238000005469 granulation Methods 0.000 description 13
- 230000003179 granulation Effects 0.000 description 13
- 230000002147 killing effect Effects 0.000 description 13
- 239000001301 oxygen Substances 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 244000052769 pathogen Species 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 238000009826 distribution Methods 0.000 description 12
- 238000011049 filling Methods 0.000 description 12
- 208000014674 injury Diseases 0.000 description 12
- 238000004806 packaging method and process Methods 0.000 description 12
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 11
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 11
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 11
- 241000276438 Gadus morhua Species 0.000 description 11
- 239000006057 Non-nutritive feed additive Substances 0.000 description 11
- 239000005642 Oleic acid Substances 0.000 description 11
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000003937 drug carrier Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 210000004207 dermis Anatomy 0.000 description 9
- 239000011261 inert gas Substances 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 9
- 230000001338 necrotic effect Effects 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 201000004384 Alopecia Diseases 0.000 description 8
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 8
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 229960004242 dronabinol Drugs 0.000 description 8
- 210000000416 exudates and transudate Anatomy 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000001814 pectin Substances 0.000 description 8
- 235000010987 pectin Nutrition 0.000 description 8
- 229920001277 pectin Polymers 0.000 description 8
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 244000025254 Cannabis sativa Species 0.000 description 7
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 7
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 7
- 229940035676 analgesics Drugs 0.000 description 7
- 239000000730 antalgic agent Substances 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 7
- 235000009120 camo Nutrition 0.000 description 7
- 235000005607 chanvre indien Nutrition 0.000 description 7
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 7
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 7
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 7
- 210000003811 finger Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 210000002414 leg Anatomy 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 239000012049 topical pharmaceutical composition Substances 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000005639 Lauric acid Substances 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 150000001336 alkenes Chemical class 0.000 description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000011487 hemp Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000155 melt Substances 0.000 description 6
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 6
- 230000009965 odorless effect Effects 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 210000002374 sebum Anatomy 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 5
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 5
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 5
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 5
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 206010037888 Rash pustular Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 235000013734 beta-carotene Nutrition 0.000 description 5
- 239000011648 beta-carotene Substances 0.000 description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 5
- 229960002747 betacarotene Drugs 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000000416 hydrocolloid Substances 0.000 description 5
- 235000012661 lycopene Nutrition 0.000 description 5
- 239000001751 lycopene Substances 0.000 description 5
- 229960004999 lycopene Drugs 0.000 description 5
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 230000001590 oxidative effect Effects 0.000 description 5
- 208000029561 pustule Diseases 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 210000003813 thumb Anatomy 0.000 description 5
- 229930003799 tocopherol Natural products 0.000 description 5
- 239000011732 tocopherol Substances 0.000 description 5
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 5
- 235000019155 vitamin A Nutrition 0.000 description 5
- 239000011719 vitamin A Substances 0.000 description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 208000035874 Excoriation Diseases 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 239000004909 Moisturizer Substances 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 231100000360 alopecia Toxicity 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 230000003676 hair loss Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001333 moisturizer Effects 0.000 description 4
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 239000011731 tocotrienol Substances 0.000 description 4
- 229930003802 tocotrienol Natural products 0.000 description 4
- 235000019148 tocotrienols Nutrition 0.000 description 4
- 125000005457 triglyceride group Chemical group 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 3
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 3
- 235000013162 Cocos nucifera Nutrition 0.000 description 3
- 244000060011 Cocos nucifera Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 238000005299 abrasion Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008162 cooking oil Substances 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 230000010339 dilation Effects 0.000 description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 description 3
- 235000004626 essential fatty acids Nutrition 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 229940013317 fish oils Drugs 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 150000004667 medium chain fatty acids Chemical class 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 229960002446 octanoic acid Drugs 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 239000005022 packaging material Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 239000013535 sea water Substances 0.000 description 3
- 230000036559 skin health Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 125000002640 tocopherol group Chemical class 0.000 description 3
- 235000019149 tocopherols Nutrition 0.000 description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 2
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 2
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010006803 Burns third degree Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- 241000183712 Cerinthe major Species 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 241000277334 Oncorhynchus Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000003493 Rhinophyma Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 210000000617 arm Anatomy 0.000 description 2
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000002358 autolytic effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 208000034526 bruise Diseases 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 2
- 229940031016 ethyl linoleate Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 229960002285 methylbenzethonium chloride Drugs 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 229940124641 pain reliever Drugs 0.000 description 2
- 239000003346 palm kernel oil Substances 0.000 description 2
- 235000019865 palm kernel oil Nutrition 0.000 description 2
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011129 pharmaceutical packaging material Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920006255 plastic film Polymers 0.000 description 2
- 239000002985 plastic film Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229940068778 tocotrienols Drugs 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000007631 vascular surgery Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- HLHYXXBCQOUTGK-FHCQLJOMSA-N (7R,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoic acid Chemical compound CC\C=C/C\C=C/C[C@H](O)\C=C/C=C/C=C/[C@H](O)C\C=C/CCC(O)=O HLHYXXBCQOUTGK-FHCQLJOMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CBLLOWCZXVHDNK-UHFFFAOYSA-N 1,2,3-trihydroxypentadecan-4-one Chemical compound CCCCCCCCCCCC(=O)C(O)C(O)CO CBLLOWCZXVHDNK-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- RLYOPPJABLAKCZ-UHFFFAOYSA-N 2-butoxycarbonylbenzenecarboperoxoic acid Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OO RLYOPPJABLAKCZ-UHFFFAOYSA-N 0.000 description 1
- 208000012260 Accidental injury Diseases 0.000 description 1
- 206010000503 Acne cystic Diseases 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000233788 Arecaceae Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- HRQKOYFGHJYEFS-UHFFFAOYSA-N Beta psi-carotene Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C HRQKOYFGHJYEFS-UHFFFAOYSA-N 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006797 Burns first degree Diseases 0.000 description 1
- 206010006802 Burns second degree Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- JZDLGAZDHCFICL-UHFFFAOYSA-N C(C)(=O)O.C(CCC(=O)O)(=O)OCCCCO Chemical compound C(C)(=O)O.C(CCC(=O)O)(=O)OCCCCO JZDLGAZDHCFICL-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 240000003068 Dioon edule Species 0.000 description 1
- 241000899749 Dypsis lutescens Species 0.000 description 1
- 241000512897 Elaeis Species 0.000 description 1
- 235000001942 Elaeis Nutrition 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000276435 Gadus Species 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 235000001835 Madeira lavender Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000026344 Nasal disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000283203 Otariidae Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 241000736029 Ruvettus pretiosus Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000005794 circulatory dysfunction Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000037416 cystogenesis Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940048820 edetates Drugs 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- 239000011663 gamma-carotene Substances 0.000 description 1
- 235000000633 gamma-carotene Nutrition 0.000 description 1
- HRQKOYFGHJYEFS-RZWPOVEWSA-N gamma-carotene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C HRQKOYFGHJYEFS-RZWPOVEWSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229940074046 glyceryl laurate Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 206010018797 guttate psoriasis Diseases 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 150000002398 hexadecan-1-ols Chemical class 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 235000001793 lemon lavender Nutrition 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 235000019802 mixed carotene Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 230000004678 mucosal integrity Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000010742 number 1 fuel oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 239000001053 orange pigment Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 108010014241 oxypolygelatine Proteins 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000004170 rice bran wax Substances 0.000 description 1
- 235000019384 rice bran wax Nutrition 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229940119224 salmon oil Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000011555 saturated liquid Substances 0.000 description 1
- 239000012173 sealing wax Substances 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 238000009283 thermal hydrolysis Methods 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 235000019145 α-tocotrienol Nutrition 0.000 description 1
- 150000003773 α-tocotrienols Chemical class 0.000 description 1
- 235000019151 β-tocotrienol Nutrition 0.000 description 1
- 150000003782 β-tocotrienols Chemical class 0.000 description 1
- 235000019150 γ-tocotrienol Nutrition 0.000 description 1
- 150000003786 γ-tocotrienols Chemical class 0.000 description 1
- 235000019144 δ-tocotrienol Nutrition 0.000 description 1
- 150000003790 δ-tocotrienols Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/965—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of inanimate origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本出願は、2018年4月13日に出願されたUSSN 62/761,951および2018年12月6日に出願されたUSSN 62/776,258の利益を主張するものであり、その両方の内容は参照により援用される。
本開示は、タラ肝油、ヘンプオイル、中鎖トリグリセリド(「MCT」)、ならびにレッドパーム濃縮物、ココナッツオイル、およびパーム油、例えば、レッドパーム油、RBDパーム油、および同様のもの、およびそれらの組み合わせから選択される植物油、ならびに任意選択でモノラウリン、C8/C10遊離脂肪酸(「遊離脂肪酸」または「FFA」)、フィッシュコラーゲン、および増粘剤、例えばミツロウ、海塩、セチルエステル、親水コロイド、例えばカルボキシメチルセルロース、および鎮痛剤を含む、局所用医薬組成物を記載し、該組成物は、無水かつ均質である。一実施形態では、タラ肝油は、約5重量%〜約30重量%の範囲の量で存在し、ヘンプオイルは、約5重量%〜約30重量%の範囲の量で存在し、上記で定義した植物油は、約10重量%〜約50重量%の範囲の量で存在し、MCTは、約5重量%〜約45重量%の範囲であり、MCTとFFAとの該重量比は、存在する場合、約4:1〜約140:1の範囲であり、海塩は、存在する場合、約0.2重量%〜約1.0重量%の範囲であり、該海塩は、典型的には、約200未満のタイラーメッシュスクリーン、つまり約74ミクロン未満の平均粒径に粉砕され、モノラウリンとセチルエステルとの重量比は、存在する場合、約0.3:1〜約2.5:1の範囲であり、セチルエステルは、存在する場合、約0.8重量%〜最大3重量%の範囲の量で存在し、タラ肝油、ヘンプシードオイル、モノラウリン、海塩、MCT、遊離脂肪酸、および植物油の総和は、組成物の約40重量%〜約100重量%の範囲である。別の実施形態では、タラ肝油は、約5重量%〜約30重量%の範囲の量で存在し、ヘンプオイルは、約5重量%〜約30重量%の範囲の量で存在し、上記で定義した植物油は、約10重量%〜約30重量%の範囲の量で存在し、MCTとFFAとの該重量比は、約4:1〜約140:1の範囲であり、海塩は、存在する場合、約0.2重量%〜約1.0重量%の範囲であり、該海塩は、典型的には、約200未満のタイラーメッシュスクリーン、つまり約74ミクロン以下の平均粒径に粉砕され、モノラウリンとセチルエステルとの重量比は、存在する場合、約0.3:1〜約2.5:1の範囲であり、セチルエステルは、存在する場合、約0.8重量%〜最大3重量%の範囲の量で存在し、タラ肝油、ヘンプシードオイル、モノラウリン、海塩、MCT、遊離脂肪酸、および植物油の総和は、組成物の約40重量%〜約100重量%の範囲である。別の実施形態では、MCTとオレイン酸(主にパーム油由来)との重量比は、存在する場合、1超である。さらなる実施形態では、本明細書に記載の組成物において、本明細書に記載の親水コロイド組成物および皮膚保護剤組成物、例えば、皮膚保護剤Aおよび皮膚保護剤Bにおいて、本開示の組成物中に存在するMCTと合計不飽和トリグリセリド(他の植物油およびタラ肝油由来)の重量の総和との重量比は、0.8超であり、別の実施形態では、1超である。本明細書に記載の他の組成物において、特にコラーゲン含有組成物および鎮痛薬を含有する組成物において、MCTと本開示に存在する合計の不飽和トリグリセリドとの重量比は、0.8未満である。さらなる実施形態では、MCTとオレイン酸との重量比は、合計一価不飽和トリグリセリドlの重量の総和に対するMCTの重量比より大きく、また前者と後者との間の差は0.3超である。一実施形態では、ヘンプオイルとタラ肝油との重量比は、約2:1〜約1:1の範囲であり、別の実施形態では、約1:1である。別の実施形態では、高オレインのレッドパーム油は、ココナッツオイルのみ、またはレッドパーム油から抽出されたカロチノイドが豊富でビタミンが豊富な画分であるレッドパーム濃縮物と組み合わせたココナッツオイルで置き換えられる。レッドパーム濃縮物は、約0.1重量%〜約2重量%の範囲で存在する。本明細書に記載の配合物のすべてに関して、ヘンプオイルおよびタラ肝油がオメガ6脂肪酸を含有するため、オメガ6脂肪酸は、本明細書に記載の配合物のすべてに存在する。オメガ6脂肪酸とオメガ3脂肪酸との重量比は、約1.0〜3.0であり、別の実施形態では、約1.2〜約2.5、さらなる実施形態では、約1.5〜約2.0の範囲である。
実施例1では、海塩およびフィッシュコラーゲンを除いて、トリグリセリドおよびミツロウを含む、以下に列挙される様々な成分を、他のトリグリセリドおよび遊離脂肪酸と60℃で十分に混合して、均質な混合物であるオイル溶融物を形成する。その後、オイル溶融物が形成され、均質になったら、海塩およびフィッシュコラーゲンを一緒に混合する。フィッシュコラーゲンは44%、オイルは42.5%である。
実施例2では、パーム油をココナッツオイルで置き換え、モノラウリンの半分をセチルエステルNFで置き換えたことを除いて実施例1と同様にして、局所用組成物を調製した。フィッシュコラーゲンおよび総和オイルは、実施例1から変化しなかった。結果を以下で表にする。
フィッシュコラーゲンを加えないことを除いて、実施例1の手順を繰り返した。手順を以下に概説する。モノラウリン/セチルエステル混合物を加熱し、冷却する。低い方の曇り点を25℃で測定した。同混合物に3.5%のミツロウを加え、高い方の雲り点を決定した。曇り点と共晶点は同じものではないが、曇り点の差および共晶点の差(ウィンドウサイズ)は比較的同じである。
実施例3のレシピを、セチルエステル有りおよび無しで繰り返した。高い方の雲り点は45.6℃、低い方の雲り点は33.1℃であった。
1.生成物は、高い方の融点、例えば、高い方の共晶曇り点の直下の充填剤供給タンク内の設定点温度で容易に維持することができる。
2.気孔内にオイルを保持している凍結したミツロウが液体となり、ポンプ剪断中にコラーゲンから流出するため、温度が高い方の融点を上回らないようにすべきである。
3.生成物を、バイアル充填機をとおしてポンプで送り込むと(1〜2g/バイアル)、幅狭で可撓性の往復式供給ホースにより、生成物が低い方の融点未満に冷却される。
a.ホースはトレースおよび絶縁することができるが、機械停止により、生成物の過熱過剰または冷却過剰のいずれかが生じる。
b.加熱過剰の生成物はバイアル内で分離し、監視員およびユーザーに不安定性を示す。
c.加熱不足の生成物はバイアルに容易に流入せず、バイアルが充填不足となる。
4.より広いウィンドウにより、中間温度の生成物を供給ポンプに導入できるようになる。回避できない冷却は依然として生じるものの、生成物が低い方の融点温度を下回る場合には、そのようなことはない。
オイル滲出[スプレー乾燥させたフィッシュコラーゲンと50:50w/w]
C8/10トリグリセリド:粗い質感、シミの目つきスポットの滲出
粗製ココナッツオイル:滑らか、滲出なし
RBDパーム油CP6:滑らか、滲出なし
ヘンプシードオイル:滑らか、滲出なし
タラ肝油:滑らか、大量の滲出
実施例7は、粗製ココナッツオイルを、モノラウリン単独による実施例3のオイル配合物を使用して高い方および低い方の共晶温度についてRBDパーム油CP6と比較し、次いでセチルエステルを加えて再加熱した後、白色ミツロウを加えて再加熱した。配合物は2つあり、1つ目はRBDパームを含むもの、2つ目は粗製ココナッツオイルを含むものであった。オイルはどちらも8.4%であった。
実施例8は、コラーゲン細孔を充填するために必要な時間を間接的に測定した(10分)。
1.表面張力が低いオイルを、噴霧乾燥したフィッシュコラーゲン細孔の奥深くに浸透するように作製した。
2.多成分ワックスシステムを、熱油を完全に浸透させ、高剪断バイアル充填を温め、流通中に冷滲出が発生しないようにするために考案した。
3.酸敗脂肪臭を防止した。
4.特別な混合装置は不要であり、むしろ標準の二重攪拌器ケトルが処理には十分である。
5.この生成物は、創傷充填剤に関するFDAの要件である電子線滅菌に耐えることができる。
実施例11は、有効成分としてリドカインを含むOTC局所鎮痛薬である。本組成物は、医薬品有効成分のための担体である。これは、タラ肝油、ヘンプオイル、MCT、セチルエステル、および遊離脂肪酸の混合物である。以下のように調製する。
洗浄BZに類似しているが、活性成分であるリドカインを含まないオイルを生成した。
実施例10のコラーゲン基質CKを使用して、最終的にトンネル創傷となった術後の感染乳癌を処理した。創傷は2週間で完全に消散した。
粗製ココナッツオイル(精製、漂白、脱臭されていないココナッツオイル)を使用して、オイル混合物中のパーム油を置き換えた。タラ肝油を、OTC皮膚保護剤承認基準(5%〜13.56%w/w)を満たすように還元した。合計MCT(例えば、加えたMCT+粗製ココナッツオイルのMCT画分)および遊離脂肪酸が増加した。
オメガオイルBXは、皮膚保護剤のOTC要件を満たす配合物である。
実施例17の配合物を、0.5%のパルミチン酸アスコルビルを排除し、+0.5%のC8 FFA(合計FFA=1.8%)で置き換えたことを除いて、再現した。
実施例20には、実施例17のオイル/ワックス混合物200gを用いたが、パルミチン酸アスコルビルは加えず、これを、溶融物が透明になるまで加熱した。曇り点が観察され、記録されるまで、溶融物を非常に穏やかに混合しながら(ビーカーを旋回させる)冷却させた。次いで、パルミチン酸アスコルビルを段階的に加え(段階あたり+0.1%)、各添加後の融点を決定した。0%のパルミチン酸アスコルビルの曇り点は64.4℃であった。
実施例22のオイル混合物は、軽度の切り傷、擦り傷、および熱傷の疼痛から一時的に保護し、それらを一時的に緩和するように設計される。実施例22では、粗製ココナッツオイルを使用する。リドカインおよびC8遊離脂肪酸は、任意選択の原料である。実施例22の凍結/解凍濁り度は0.2NTUである。対応するMCTの減少を伴う1.0%のリドカイン濃度は、濁度が0.5NTUである。
実施例24では、親水コロイド皮膚接触層とフォームとの間に任意選択のフォーム層を追加する。親水性フォームの裏打ちを追加することにより、滲出の多い創傷を親水コロイドで治療することができるようになる。
パルミチン酸アスコルビルを加えて、コラーゲン球をともに緊密に接着し、すべての浸潤経路の断面積を固着させる。
窒素ガスを泡立てて周囲温度の剛性基質にし、ポンプ送達または押出しされたときに屈曲し得る可撓性のカプセルかされた気泡を形成する。
40%超のフィッシュコラーゲンは、創傷床に構造を構築するのを助ける。
120°F耐久試験では浸潤がなかった。
皮膚に臭気はない。
MCTオイルは8%に増加した
生成物は流動性のペーストである。
レッドパーム濃縮物は0.12%w/w超である
生成物は4つの異なる共晶温度を有する
122°−パルミチン酸アスコルビルが凍結する
112°F−ミツロウが凍結する
98.5°F−モノラウリン/セチルエステルNFが凍結する
約75°F−ココナッツオイルが凍結する
FFAは1.3%に減少した
モノラウリンは4.3%に増加した
CLOは11.4%に減少した
トリグリセリド/フィッシュコラーゲン比は1.000である
一見したところ極めて軽微なこれらの差異は重要なものである。
充填温度を100°Fに上昇させる
わずかに高い温度により粘度が低下するが、110Fでは、泡立てた基質から気体が放出され、粘度は500,000cP超に跳ね上がる(「ハードチーズ」)
CLOを減少させて、高浸潤トリグリセリドを減少させる
MCTを増加させて、フィッシュコラーゲンに直接吸収されるオイルを増加させる
FFAを増加させて、粘度を低下させる
ワックスを増加させて、細孔を塞ぐ。
トリグリセリド/フィッシュコラーゲン比は1.000で最適化する
親水コロイドで構成される次の組成物を、次のように調製する。
成分 重量%
MCTオイル 4.8
粗製ココナッツオイル 4.8
ヘンプオイル 1.2
タラ肝油 1.2
カルボキシメチルセルロース 50.0
加工助剤、粘着付与剤、水などのその他の成分 38
次の化合物で構成される次の組成物を調製した。
MCTオイル 32
C8 FFA 0.3
モノラウリン 0.6
セチルエステル 1.0
リドカイン 0.8
RBDパーム油 14.6
ヘンプオイル 25.2
タラ肝油 25.2
次の化合物で構成される次の組成物を調製した。
MCTオイル 40
C8 FFA 0.3
RBDパーム油 18
粗製ココナッツオイル 20
ヘンプオイル 10
タラ肝油 10
モノラウリン 0.6
セチルエステル 1.0
ラベンダーオイル 0.02
レモンオイル 0.08
次の化合物で構成される次の組成物を調製した。
MCTオイル 40
C8 FFA 0.3
レッドパーム濃縮物 0.10
RBDパーム油 20
粗製ココナッツオイル 18
ヘンプオイル 10
タラ肝油 10
モノラウリン 0.6
セチルエステル 1.0
Claims (70)
- 約10cP〜約100cPの範囲の粘度および約20mN/m〜約35mN/mの範囲の表面張力を有する油性溶液を含み、タラ肝油、フィッシュコラーゲン、ヘンプシードオイル、モノラウリン、中鎖トリグリセリド(「MCT」)、遊離脂肪酸(「FFA」)、ならびにレッドパーム濃縮物、ココナッツオイル、およびパーム油からなる群から選択される植物油、ならびに海塩および濃厚剤、ならびにセチルエステルで構成され、無水かつ均質である、医薬組成物であって、前記タラ肝油が、約5重量%〜約15重量%の範囲の量で存在し、ヘンプオイルが、約15重量%〜約10重量%の範囲の量で存在し、MCTが、約6重量%〜約12重量%の量で存在し、フィッシュコラーゲンが、約35重量%〜約50重量%の範囲の量で存在し、遊離脂肪酸が、約0.5重量%〜約1.5重量%で存在し、セチル酸が、約0.8重量%〜3重量%で存在し、前記植物油が、8重量%〜約30重量%の範囲の量で存在し、前記タラ肝油、ヘンプシードオイル、フィッシュコラーゲン、モノラウリン、海塩、MCT、遊離脂肪酸、および植物油の合計が、前記組成物の約80重量%〜約100重量%の範囲であり、MCTとFFAとの重量比が、約5:1〜約15:1の範囲であり、海塩が、約0.2重量%〜約1重量%で存在し、前記海塩は、平均サイズが約74ミクロン未満である結晶を有し、モノラウリンとセチルエステルとの重量比が、約0.8:〜約2.5:1の範囲であり、前記組成物が、不飽和トリグリセリドを含有し、前記MCTと不飽和トリグリセリドとの重量比が、1.0未満であり、前記組成物が、オメガ3およびオメガ6脂肪酸でも構成され、オメガ6脂肪酸とオメガ3脂肪酸との重量比が、約1.0〜約3.0の範囲であり、ヘンプオイルとタラ肝油との重量比が、約2:1〜約1:1の範囲である、組成物。
- ヘンプオイルとタラ肝油との重量比が約1:1である、請求項1に記載の組成物。
- 前記フィッシュコラーゲンおよび前記タラ肝油の重量の合計が、約50重量%〜約65重量%の範囲である、請求項1または2に記載の組成物。
- 前記フィッシュコラーゲン対とラ肝フィッシュオイルとの重量比が、約2.5〜約5.5の範囲である、請求項1〜3のいずれか一項に記載の組成物。
- FFAが、約0.8重量%〜約1.4重量%の範囲の量で存在する、請求項1〜4のいずれか一項に記載の組成物。
- MCTが、約7重量%〜約9重量%の範囲の量で存在する、請求項1〜5のいずれか一項に記載の組成物。
- MCTとFFAとの重量比が、約10:1〜6:1の範囲である、請求項1〜6のいずれか一項に記載の組成物。
- オメガ6脂肪酸とオメガ3脂肪酸との重量比が、約1,2〜約2.5の範囲である、請求項1〜7のいずれか一項に記載の組成物。
- オメガ6脂肪酸とオメガ3脂肪酸との重量比が、約1.5〜約1.9の範囲である、請求項1〜8のいずれか一項に記載の組成物。
- レッドパーム濃縮物が、約0.20〜約0.4重量%の範囲の量で存在する、請求項1〜9のいずれか一項に記載の組成物。
- ヘンプオイルが、約12〜約14重量%の範囲の量で存在する、請求項1〜10のいずれか一項に記載の組成物。
- ミツロウが追加で存在する、請求項1〜11のいずれか一項に記載の組成物。
- ミツロウが、約2重量%〜約6重量%の範囲の量で存在する、請求項12に記載の組成物。
- パルミチン酸アスコルビルが追加で存在する、請求項1〜13のいずれか一項に記載の組成物。
- パルミチン酸アスコルビルが、約0.3〜約0.6重量%の範囲の量で存在する、請求項14に記載の組成物。
- 親水コロイド組成物MCT、粗製ココナッツオイル、タラ肝油、ヘンプオイル、および親水コロイドであって、前記タラ肝油が、約7〜15重量%の量で存在し、ヘンプオイルが、約7〜15重量%の量で存在し、ヘンプオイルとタラ肝油との比が、約2:1〜約1:1の範囲であり、MCTが、約30〜約45重量%の量で存在し、粗製ココナッツオイルが、約30重量%〜約45重量%の量で存在し、MCTと粗製ココナッツオイルとの重量比が、約0.8:1〜1.2:であり、親水コロイドが、約10重量%〜約50重量%の範囲の量で存在し、前記ココナッツオイル、MCT、親水コロイド、ヘンプオイル、およびタラ肝油の合計が、約90重量%〜約100重量%の範囲であり、前記組成物が、フィッシュコラーゲンを含まず、前記組成物が、不飽和トリグリセリドを含み、前記MCTと不飽和トリグリセリドとの重量比が、0.8超であり、前記組成物が、オメガ6およびオメガ3脂肪酸でも構成され、前記オメガ6脂肪酸とオメガ3脂肪酸との重量比が、約1:1〜約3:1の範囲である、親水コロイド組成物。
- 前記ヘンプオイルとタラ肝油との重量比が、約1:1〜約1.5:1である、請求項16に記載の親水コロイド組成物。
- 前記ヘンプオイルとタラ肝油との重量比が、約1:1である、請求項16または17に記載の親水コロイド組成物。
- 前記オメガ6脂肪酸とオメガ3脂肪酸との重量比が、約1.5〜約1.9の範囲である、請求項16〜18のいずれか一項に記載の親水コロイド組成物。
- MCTオイルが、約35重量%〜約42重量%の範囲の量で存在し、粗製ココナッツオイルが、約35重量%〜約42重量%の範囲の量で存在し、ヘンプオイルが、約8重量%〜約12重量%の量で存在し、タラ肝油が、約8重量%〜約12重量%の範囲の量で存在し、前記親水コロイドが。約15重量%〜約40重量%の量で存在する、請求項16〜19のいずれか一項に記載の親水コロイド組成物。
- 前記MCTと粗製ココナッツオイルとの重量比が、約1:1である、請求項16〜20のいずれか一項に記載の親水コロイド組成物。
- 前記オメガ6脂肪酸とオメガ3脂肪酸との重量比が、約1.5〜約1.9の範囲である、請求項16〜21のいずれか一項に記載の親水コロイド組成物。
- 前記親水コロイドがカルボキシメチルセルロースである、請求項16〜22のいずれか一項に記載の親水コロイド組成物。
- MCTオイル、FFA、モノラウリン、セチルエステル、疎水性鎮痛剤、植物油、ヘンプオイル、およびタラ肝油を含む鎮痛剤組成物であって、ヘンプオイルが、約10重量%〜約35重量%の範囲の量で存在し、タラ肝油が、約10重量%〜約35重量%の範囲の量で存在し、疎水性鎮痛剤が、約0.6重量%〜約1.2重量%の範囲の量で存在し、MCTオイルが、約20〜約40重量%の範囲の量で存在し、C8/C10脂肪酸が、約0.1〜約1.0重量%の範囲の量で存在し、モノラウリンが、約0.3〜約2.0重量%の範囲の量で存在し、植物油が、約10重量%〜約30重量%の範囲の量で存在し、セチルエステルが、約0.5〜約2.5重量%の範囲の量で存在し、前記MCTオイル、FFA、モノラウリン、セチルエステル、疎水性鎮痛剤、植物油、ヘンプオイル、およびタラ肝油の合計が、前記組成物の約80重量%〜約100重量%の範囲であり、前記組成物が、不飽和トリグリセリドを含有し、前記MCTと不飽和トリグリセリドとの重量比が、0.8未満であり、前記組成物が、オメガ6およびオメガ3脂肪酸でも構成され、前記オメガ6脂肪酸とオメガ3脂肪酸との重量比が、約1:1〜約3:1の範囲であり、ヘンプオイル対タラ肝油が、約1:1〜約2:1の範囲であり、前記組成物が、フィッシュコラーゲンを含まない、鎮痛剤組成物。
- ヘンプオイルが、前記組成物の約22重量%〜約30重量%の範囲の量で存在する、請求項24に記載の鎮痛剤組成物。
- タラ肝油が、前記組成物の約22重量%〜約30重量%の範囲の量で存在する、請求項24または25に記載の鎮痛剤組成物。
- 前記ヘンプオイルとタラ肝油との重量比が、約1.5:1〜約1:1である、請求項24〜26のいずれか一項に記載の鎮痛剤組成物。
- 前記ヘンプオイルとタラ肝油との重量比が、約1:1である、請求項24〜27のいずれか一項に記載の鎮痛剤組成物。
- C8/C10遊離脂肪酸が、前記組成物の約0.20重量%〜約0.50重量%の範囲の量で存在する、請求項24〜28のいずれか一項に記載の鎮痛剤組成物。
- C8/C10遊離脂肪酸が、前記組成物の約0.25重量%〜約0.35重量%の範囲の量で存在する、請求項24〜29のいずれか一項に記載の鎮痛剤組成物。
- MCTとC8/C10遊離脂肪酸との重量比が、約90:1〜140:1の範囲である、請求項24〜30のいずれか一項に記載の鎮痛剤組成物。
- MCTとC8/C10遊離脂肪酸との重量比が、約100:1〜120:1の範囲である、請求項24〜31のいずれか一項に記載の鎮痛剤組成物。
- モノラウリンが、約0.3重量%〜約0.99重量%の範囲の量で存在する、請求項24〜32のいずれか一項に記載の鎮痛剤組成物。
- モノラウリンが、前記組成物の約0.5重量%〜約0.75重量%の範囲の量で存在する、請求項24〜33のいずれか一項に記載の鎮痛剤組成物。
- モノラウリンが、前記組成物の約0.55重量%〜約0.65重量%の範囲の量で存在する、請求項24〜34のいずれか一項に記載の鎮痛剤組成物。
- セチルエステルが、前記組成物の約1重量%〜3重量%の範囲の量で存在する、請求項24〜35のいずれか一項に記載の鎮痛剤組成物。
- セチルエステルとモノラウリンとの重量比が、約1:0.5〜約1:0.7の範囲である、請求項24〜36のいずれか一項に記載の鎮痛剤組成物。
- 存在する植物油の量が、前記組成物の約12重量%〜約17重量%の範囲である、請求項24〜37のいずれか一項に記載の鎮痛剤組成物。
- 前記オメガ6脂肪酸とオメガ3脂肪酸との重量比が、約1.5〜約1.9の範囲である、請求項24〜38のいずれか一項に記載の鎮痛剤組成物。
- 前記鎮痛剤がロジカインである、請求項24〜39のいずれか一項に記載の鎮痛剤組成物。
- 皮膚保護剤であって、約5重量%〜約15重量%の範囲の量で存在するヘンプオイルと、約5重量%〜約15重量%の範囲の量で存在するタラ肝油と、約30重量%〜約50重量%の範囲の量で存在するMCTオイルと、約0.1〜約1.0重量%の範囲の量で存在するC8/C10脂肪酸と、約0.3〜約2.0重量%の範囲の量で存在するモノラウリンと、約30重量%〜約50重量%の範囲の量で存在する植物油と、約0.5〜約2.5重量%の範囲の量で存在するセチルエステルと、を含み、前記MCTオイル、FFA、モノラウリン、セチルエステル、植物油の合計が、前記組成物の約80重量%〜約100重量%の範囲であり、ヘンプオイルとタラ肝油との重量比が、約1:1〜約2:1の範囲であり、前記組成物が、不飽和トリグリセリドを含有し、前記MCTと不飽和トリグリセリドとの重量比が、0.8超であり、前記組成物が、オメガ6およびオメガ3脂肪酸でも構成され、オメガ6脂肪酸とオメガ3脂肪酸との重量比が、約1:1〜約3:1の範囲であり、前記組成物が、フィッシュコラーゲンを含まない、皮膚保護剤。
- ヘンプオイルが、前記組成物の約7重量%〜約13重量%の範囲の量で存在する、請求項41に記載の皮膚保護剤。
- ヘンプオイルが、前記組成物の約9重量%〜約11重量%の範囲の量で存在する、請求項41または42に記載の皮膚保護剤。
- ヘンプオイルが、前記組成物の約10重量%で存在する、請求項41〜43のいずれか一項に記載の皮膚保護剤。
- タラ肝油が、前記組成物の約7重量%〜約13重量%の範囲の量で存在する、請求項41〜44のいずれか一項に記載の皮膚保護剤。
- タラ肝油が、前記組成物の約9重量%〜約11重量%で存在する、請求項41〜45のいずれか一項に記載の皮膚保護剤。
- タラ肝油が、前記組成物の約10重量%で存在する、請求項41〜46のいずれか一項に記載の皮膚保護剤。
- 前記ヘンプオイルとタラ肝油との重量比が、約1:1〜約1.5:1である、請求項41〜47のいずれか一項に記載の皮膚保護剤。
- 前記ヘンプオイルとタラ肝油との重量比が、約1:1である、請求項41〜48のいずれか一項に記載の皮膚保護剤。
- 前記C8/C10遊離脂肪酸が、前記組成物の約0.15重量%〜約1.00重量%の範囲の量で存在する、請求項41〜49のいずれか一項に記載の皮膚保護剤。
- 前記C8/C10遊離脂肪酸が、約0.20重量%〜約0.50重量%で存在する、請求項41〜50のいずれか一項に記載の皮膚保護剤。
- 前記C8/C10遊離脂肪酸が、約0.25重量%〜約0.35重量%で存在する、請求項41〜51のいずれか一項に記載の皮膚保護剤。
- MCTが、前記組成物の約30重量%〜約50重量%の範囲の量で存在する、請求項41〜52のいずれか一項に記載の皮膚保護剤。
- MCTが、前記組成物の約35重量%〜約45重量%の範囲の量で存在する、請求項41〜53のいずれか一項に記載の皮膚保護剤。
- 前記MCTとC8/C10遊離脂肪酸との重量比が、約90:1〜140:1の範囲である、請求項41〜54のいずれか一項に記載の皮膚保護剤。
- 前記MCTとC8/C10遊離脂肪酸との重量比が、約100:1〜120:1の範囲である、請求項41〜55のいずれか一項に記載の皮膚保護剤。
- モノラウリンが、前記組成物の約0.3重量%〜約0.99重量%の範囲の量で存在する、請求項41〜56のいずれか一項に記載の皮膚保護剤。
- モノラウリンが、前記組成物の約0.5重量%〜約0.75重量%で存在する、請求項41〜57のいずれか一項に記載の皮膚保護剤。
- モノラウリンが、前記組成物の約0.55重量%〜約0.65重量%で存在する、請求項41〜58のいずれか一項に記載の皮膚保護剤。
- セチルエステルが、前記組成物の約0 1重量%〜3重量%の範囲の量で存在する、請求項41〜59のいずれか一項に記載の皮膚保護剤。
- 前記セチルエステルとモノラウリンとの重量比が、約1:0.5〜約1:0.7の範囲である、請求項41〜60のいずれか一項に記載の皮膚保護剤。
- 存在する植物油の量が、前記組成物の約35重量%〜約45重量%の範囲である、請求項41〜61のいずれか一項に記載の皮膚保護剤。
- 存在する植物油の量が、前記組成物の約36重量%〜約40重量%の範囲である、請求項41〜62のいずれか一項に記載の皮膚保護剤。
- 前記オメガ6脂肪酸とオメガ3脂肪酸との重量比が、約1;1〜約1.5:1の範囲である、請求項41〜63のいずれか一項に記載の皮膚保護剤。
- 前記植物油が、粗製ココナッツオイルおよびRBDパーム油を含むが、レッドパーム濃縮物を含まず、前記粗製ココナッツオイルとRBDパーム油との重量比が、0.55〜0.45の範囲である、請求項41〜64のいずれか一項に記載の皮膚保護剤。
- 前記粗製ココナッツオイルとRBDパーム油との重量比が、約0.52〜約0.48の範囲である、請求項41〜65のいずれか一項に記載の皮膚保護剤。
- 前記植物油が、レッドパーム濃縮物、粗製ココナッツオイル、およびRBDパーム油を含む、請求項41〜64のいずれか一項に記載の皮膚保護剤。
- 前記RBDパーム油と粗製ココナッツオイルとの重量比が、約0.55〜約0.45の範囲である、請求項67に記載の皮膚保護剤。
- 前記RBDパーム油と粗製ココナッツオイルとの重量比が、約0.52〜約0.48の範囲である、請求項67または68に記載の皮膚保護剤。
- 前記レッドパーム濃縮物が、前記組成物の約0.01重量%〜約0.20重量%の範囲の量で存在する、請求項67〜69のいずれか一項に記載の皮膚保護剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024028102A JP2024059876A (ja) | 2018-04-13 | 2024-02-28 | 創傷および皮膚障害を治療するためのタラ肝油で構成される局所用組成物 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862761951P | 2018-04-13 | 2018-04-13 | |
US62/761,951 | 2018-04-13 | ||
US201862776258P | 2018-12-06 | 2018-12-06 | |
US62/776,258 | 2018-12-06 | ||
PCT/US2019/027396 WO2019200364A1 (en) | 2018-04-13 | 2019-04-12 | Topical composition comprised of cod liver oil for treating wounds and skin disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024028102A Division JP2024059876A (ja) | 2018-04-13 | 2024-02-28 | 創傷および皮膚障害を治療するためのタラ肝油で構成される局所用組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021521281A true JP2021521281A (ja) | 2021-08-26 |
JPWO2019200364A5 JPWO2019200364A5 (ja) | 2022-04-19 |
JP7501921B2 JP7501921B2 (ja) | 2024-06-18 |
Family
ID=68163302
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021505627A Active JP7501921B2 (ja) | 2018-04-13 | 2019-04-12 | 創傷および皮膚障害を治療するためのタラ肝油で構成される局所用組成物 |
JP2024028102A Pending JP2024059876A (ja) | 2018-04-13 | 2024-02-28 | 創傷および皮膚障害を治療するためのタラ肝油で構成される局所用組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024028102A Pending JP2024059876A (ja) | 2018-04-13 | 2024-02-28 | 創傷および皮膚障害を治療するためのタラ肝油で構成される局所用組成物 |
Country Status (5)
Country | Link |
---|---|
US (3) | US11903977B2 (ja) |
EP (1) | EP3773466A4 (ja) |
JP (2) | JP7501921B2 (ja) |
CA (1) | CA3096482A1 (ja) |
WO (1) | WO2019200364A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3173441A1 (en) * | 2020-04-21 | 2021-10-28 | Omeza Holdings, Inc. | Novel anhydrous compositions comprised of marine oils |
WO2023205207A1 (en) * | 2022-04-19 | 2023-10-26 | Omeza Holdings, Inc. | Topical compositions for reducing scarring |
KR20240062990A (ko) | 2022-10-28 | 2024-05-09 | 오메자 홀딩스 인코포레이티드 | 부상 및/또는 피부 병태의 치료를 위한 조성물 및 방법 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06505959A (ja) * | 1990-05-07 | 1994-07-07 | ボッコー バリー アイ | 安定な脱臭油及びその医薬組成物の方法及び製剤 |
JP2000191525A (ja) * | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
US20100074963A1 (en) * | 2008-09-23 | 2010-03-25 | Biolife, L.L.C. | Red Palm Oil and Fish Oil Wound Dressing |
JP2017075111A (ja) * | 2015-10-14 | 2017-04-20 | 東光薬品工業株式会社 | 外用組成物 |
US20170281689A1 (en) * | 2016-04-04 | 2017-10-05 | Omeza LLC | Fish oil topical composition |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3628796A (en) | 1969-02-20 | 1971-12-21 | Itsuki Ban | Apparatus for shifting magnetic head in multitrack tape player |
US7297668B2 (en) * | 2003-04-03 | 2007-11-20 | Colgate-Palmolive Company | Composition |
EP1827393A4 (en) * | 2004-12-09 | 2012-04-18 | Insys Therapeutics Inc | DRONABINOL FORMULATIONS WITH LABORATORY TEMPERATURE |
US20090035398A1 (en) * | 2007-03-29 | 2009-02-05 | Raymond Williams | Topical formulations |
AU2008306317B2 (en) * | 2007-10-02 | 2012-04-26 | Lg Household & Health Care Ltd. | Cosmetic or pharmaceutical composition for topical application |
FR2929516A1 (fr) * | 2008-04-03 | 2009-10-09 | Carilene Lab | Composition dermatologique utilisable notamment pour le soin et la prevention des escarres |
US8741373B2 (en) | 2010-06-21 | 2014-06-03 | Virun, Inc. | Compositions containing non-polar compounds |
US20160073645A1 (en) * | 2014-09-11 | 2016-03-17 | Parafora Communications | Holding device and kit |
US20170189323A1 (en) * | 2015-12-30 | 2017-07-06 | Ryan Charles Ballenas | All-natural sunscreen |
-
2019
- 2019-04-12 JP JP2021505627A patent/JP7501921B2/ja active Active
- 2019-04-12 EP EP19784767.6A patent/EP3773466A4/en active Pending
- 2019-04-12 US US17/047,332 patent/US11903977B2/en active Active
- 2019-04-12 CA CA3096482A patent/CA3096482A1/en active Pending
- 2019-04-12 WO PCT/US2019/027396 patent/WO2019200364A1/en active Application Filing
-
2023
- 2023-06-01 US US18/327,267 patent/US20230338435A1/en active Pending
- 2023-06-01 US US18/327,278 patent/US20240024374A1/en active Pending
-
2024
- 2024-02-28 JP JP2024028102A patent/JP2024059876A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06505959A (ja) * | 1990-05-07 | 1994-07-07 | ボッコー バリー アイ | 安定な脱臭油及びその医薬組成物の方法及び製剤 |
JP2000191525A (ja) * | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
US20100074963A1 (en) * | 2008-09-23 | 2010-03-25 | Biolife, L.L.C. | Red Palm Oil and Fish Oil Wound Dressing |
JP2017075111A (ja) * | 2015-10-14 | 2017-04-20 | 東光薬品工業株式会社 | 外用組成物 |
US20170281689A1 (en) * | 2016-04-04 | 2017-10-05 | Omeza LLC | Fish oil topical composition |
Also Published As
Publication number | Publication date |
---|---|
JP7501921B2 (ja) | 2024-06-18 |
WO2019200364A1 (en) | 2019-10-17 |
EP3773466A1 (en) | 2021-02-17 |
US20230338435A1 (en) | 2023-10-26 |
JP2024059876A (ja) | 2024-05-01 |
EP3773466A4 (en) | 2022-03-09 |
US20210161972A1 (en) | 2021-06-03 |
US20240024374A1 (en) | 2024-01-25 |
CA3096482A1 (en) | 2019-10-17 |
US11903977B2 (en) | 2024-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8815298B2 (en) | Therapeutic composition comprising honey or a honey derivative | |
US20240024374A1 (en) | Topical composition comprised of cod li ver oil for treating wounds and skin disorders | |
KR102354954B1 (ko) | 어유 국소 조성물 | |
JP7313118B2 (ja) | ザクロ種子油、rosa canina果実油、およびinula viscosa含油樹脂または抽出物を含有する組成物 | |
US20230165825A1 (en) | Novel anhydrous compositions comprised of marine oils | |
US20100074963A1 (en) | Red Palm Oil and Fish Oil Wound Dressing | |
EA011723B1 (ru) | Композиции для местного применения | |
US10426803B2 (en) | Topical medicament for skin and mucosal injuries | |
RU2369377C1 (ru) | Фитобальзам для регенерации кожи "инсофит" | |
Gaurav et al. | Home remedies in dermatology | |
US20240139138A1 (en) | Composition of and method for treating injury and/or skin conditions | |
WO2023205207A1 (en) | Topical compositions for reducing scarring |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220411 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220411 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20221018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221018 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230518 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230720 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230821 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240228 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240307 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240507 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240530 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7501921 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |